Interferon γ regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies

Rosalind P. Fabunmi, W. Christian Wigley, Philip J. Thomas, George N. DeMartino

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

PA28 is an interferon γ (IFNγ) inducible proteasome activator required for presentation of certain major histocompatibility (MHC) class I antigens. Under basal conditions in HeLa and Hep2 cells, a portion of nuclear PA28 is concentrated at promyelocytic leukemia oncoprotein (PML)-containing bodies also commonly known as PODs or ND10. IFNγ treatment greatly increased the number and size of the PA28- and PML-containing bodies, and the effect was further enhanced in serum-deprived cells. PML bodies are disrupted in response to certain viral infections and in diseases such as acute promyelocytic leukemia (APL). Like PML, PA28 was delocalized from PML bodies by expression of the cytomegalovirus protein, IE1, and in NB4 cells, an APL model line. Moreover, retinoic acid treatment, which causes remission of APL in patients and reformation of PML-containing bodies in NB4 cells, relocalized PA28 to this site. In contrast, the proteasome, the functional target of PA28, was not detected at PML bodies under basal conditions in HeLa and Hep2 cells, but IFNγ promoted accumulation of 'immunoproteasomes' at this site. These results establish PA28 as a novel component of nuclear PML bodies, and suggest that PA28 may assemble or activate immunoproteasomes at this site as part of its role in proteasome-dependent MHC class I antigen presentation.

Original languageEnglish (US)
Pages (from-to)29-36
Number of pages8
JournalJournal of Cell Science
Volume114
Issue number1
StatePublished - 2001

Fingerprint

Oncogene Proteins
Proteasome Endopeptidase Complex
Interferons
Leukemia
Acute Promyelocytic Leukemia
HeLa Cells
Histocompatibility Antigens Class I
Histocompatibility
Antigen Presentation
Virus Diseases
Tretinoin
Therapeutics
Serum

Keywords

  • IFN gamma
  • LMP
  • PA28
  • PML
  • Proteasome

ASJC Scopus subject areas

  • Cell Biology

Cite this

Interferon γ regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies. / Fabunmi, Rosalind P.; Christian Wigley, W.; Thomas, Philip J.; DeMartino, George N.

In: Journal of Cell Science, Vol. 114, No. 1, 2001, p. 29-36.

Research output: Contribution to journalArticle

@article{fc686e8f691a4590a00f6bd25bc67361,
title = "Interferon γ regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies",
abstract = "PA28 is an interferon γ (IFNγ) inducible proteasome activator required for presentation of certain major histocompatibility (MHC) class I antigens. Under basal conditions in HeLa and Hep2 cells, a portion of nuclear PA28 is concentrated at promyelocytic leukemia oncoprotein (PML)-containing bodies also commonly known as PODs or ND10. IFNγ treatment greatly increased the number and size of the PA28- and PML-containing bodies, and the effect was further enhanced in serum-deprived cells. PML bodies are disrupted in response to certain viral infections and in diseases such as acute promyelocytic leukemia (APL). Like PML, PA28 was delocalized from PML bodies by expression of the cytomegalovirus protein, IE1, and in NB4 cells, an APL model line. Moreover, retinoic acid treatment, which causes remission of APL in patients and reformation of PML-containing bodies in NB4 cells, relocalized PA28 to this site. In contrast, the proteasome, the functional target of PA28, was not detected at PML bodies under basal conditions in HeLa and Hep2 cells, but IFNγ promoted accumulation of 'immunoproteasomes' at this site. These results establish PA28 as a novel component of nuclear PML bodies, and suggest that PA28 may assemble or activate immunoproteasomes at this site as part of its role in proteasome-dependent MHC class I antigen presentation.",
keywords = "IFN gamma, LMP, PA28, PML, Proteasome",
author = "Fabunmi, {Rosalind P.} and {Christian Wigley}, W. and Thomas, {Philip J.} and DeMartino, {George N.}",
year = "2001",
language = "English (US)",
volume = "114",
pages = "29--36",
journal = "Journal of Cell Science",
issn = "0021-9533",
publisher = "Company of Biologists Ltd",
number = "1",

}

TY - JOUR

T1 - Interferon γ regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies

AU - Fabunmi, Rosalind P.

AU - Christian Wigley, W.

AU - Thomas, Philip J.

AU - DeMartino, George N.

PY - 2001

Y1 - 2001

N2 - PA28 is an interferon γ (IFNγ) inducible proteasome activator required for presentation of certain major histocompatibility (MHC) class I antigens. Under basal conditions in HeLa and Hep2 cells, a portion of nuclear PA28 is concentrated at promyelocytic leukemia oncoprotein (PML)-containing bodies also commonly known as PODs or ND10. IFNγ treatment greatly increased the number and size of the PA28- and PML-containing bodies, and the effect was further enhanced in serum-deprived cells. PML bodies are disrupted in response to certain viral infections and in diseases such as acute promyelocytic leukemia (APL). Like PML, PA28 was delocalized from PML bodies by expression of the cytomegalovirus protein, IE1, and in NB4 cells, an APL model line. Moreover, retinoic acid treatment, which causes remission of APL in patients and reformation of PML-containing bodies in NB4 cells, relocalized PA28 to this site. In contrast, the proteasome, the functional target of PA28, was not detected at PML bodies under basal conditions in HeLa and Hep2 cells, but IFNγ promoted accumulation of 'immunoproteasomes' at this site. These results establish PA28 as a novel component of nuclear PML bodies, and suggest that PA28 may assemble or activate immunoproteasomes at this site as part of its role in proteasome-dependent MHC class I antigen presentation.

AB - PA28 is an interferon γ (IFNγ) inducible proteasome activator required for presentation of certain major histocompatibility (MHC) class I antigens. Under basal conditions in HeLa and Hep2 cells, a portion of nuclear PA28 is concentrated at promyelocytic leukemia oncoprotein (PML)-containing bodies also commonly known as PODs or ND10. IFNγ treatment greatly increased the number and size of the PA28- and PML-containing bodies, and the effect was further enhanced in serum-deprived cells. PML bodies are disrupted in response to certain viral infections and in diseases such as acute promyelocytic leukemia (APL). Like PML, PA28 was delocalized from PML bodies by expression of the cytomegalovirus protein, IE1, and in NB4 cells, an APL model line. Moreover, retinoic acid treatment, which causes remission of APL in patients and reformation of PML-containing bodies in NB4 cells, relocalized PA28 to this site. In contrast, the proteasome, the functional target of PA28, was not detected at PML bodies under basal conditions in HeLa and Hep2 cells, but IFNγ promoted accumulation of 'immunoproteasomes' at this site. These results establish PA28 as a novel component of nuclear PML bodies, and suggest that PA28 may assemble or activate immunoproteasomes at this site as part of its role in proteasome-dependent MHC class I antigen presentation.

KW - IFN gamma

KW - LMP

KW - PA28

KW - PML

KW - Proteasome

UR - http://www.scopus.com/inward/record.url?scp=0035147230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035147230&partnerID=8YFLogxK

M3 - Article

VL - 114

SP - 29

EP - 36

JO - Journal of Cell Science

JF - Journal of Cell Science

SN - 0021-9533

IS - 1

ER -